v2vmedtech, inc.
$0.2 million
April 18, 2023
Company purchased 30% of the equity of v2vmedtech and concurrently contributed $0.2 million under a stock purchase agreement.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Company purchased 30% of the equity of v2vmedtech and concurrently contributed $0.2 million under a stock purchase agreement.
Company agreed to provide development services to v2vmedtech in exchange for equity, with development contributions paid in five stages under the Development Agreement.
v2vmedtech granted the company a perpetual and exclusive license to the Developed Technology and Data for medical device applications other than leaky valve devices.
Company break fees for terminating development activities (from $0.2 million in Stage 1 up to $1.0 million in Stage 5) and company payment of v2vmedtech's operational costs up to an amount set annually by its board.
Loading...
